Author/Authors :
Ghasemi، Ali نويسنده Department of Computer Science, South Tehran Branch, Islamic Azad University, Tehran, Iran , , Ghotaslou، Abbas نويسنده Department of Hematology, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, IR Iran , , Mohammadi، Mohsen نويسنده , , Abbasian، Sadegh نويسنده Department of Hematology, Faculty of Allied Medical
Sciences, Tehran University of Medical Sciences, Tehran, IR
Iran , , Ghaffari، Kazem نويسنده Department of Hematology, School of Allied Medical Sciences, Arak University of Medical Sciences, Arak, IR Iran ,
Abstract :
Background In acute myeloid leukemia (AML), a large number of
tumor suppressor genes are silenced through DNA methylation such as
CDKN2B and p73. Wnt inhibitory factor 1 (WIF1) and Dickkopf-1 (DKK-1)
are negative regulator of the Wnt signaling pathway. Objectives In the
present study, we studied the methylation status of WIF1 and DKK-1 genes
in AML patients. Patients and Methods In this case-control study, blood
samples from 120 AML patients and 25 healthy control subjects collected,
isolated DNA was treated with sodium bisulphite and examined by
methylation specific PCR (MS-PCR) with primers specific for methylated
and unmethylated sequences of the WIF1 and DKK-1 genes. Results The
frequency of aberrant hypermethylation of WIF1 and DKK-1 genes in AML
patients determined 35% (42/120) and 28.3% (34/120), respectively. In
addition, for all subjects in control group, methylation of WIF1 and
DKK-1 genes were negative. Patients with M0 subtype of
French-American-British (FAB)-AML had the highest incidence of
hypermethylation of WIF1 (P = 0.003) and DKK-1 (P = 0.005) genes.
Conclusions The present study showed that, like many solid tumors, WIF1
and DKK-1 genes methylation also occurs in AML. The study of other
antagonists of Wnt signaling pathway are recommended.
